(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of 11.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.07%.
Connect Biopharma Holdings's revenue in 2025 is $26,033,000.On average, 1 Wall Street analysts forecast CNTB's revenue for 2025 to be $2,186,293,716, with the lowest CNTB revenue forecast at $2,186,293,716, and the highest CNTB revenue forecast at $2,186,293,716. On average, 1 Wall Street analysts forecast CNTB's revenue for 2026 to be $1,106,984,160, with the lowest CNTB revenue forecast at $1,106,984,160, and the highest CNTB revenue forecast at $1,106,984,160.
In 2027, CNTB is forecast to generate $1,978,734,186 in revenue, with the lowest revenue forecast at $1,909,547,676 and the highest revenue forecast at $2,047,920,696.